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Background
Lamivudine is a dideoxy nucleoside analogue – NRTI,
widely used in the treatment of HIV infection. It is a
best tolerated drug with long term safety profile and
most preferred in all regimens. Skin hypersensitivity
reactions to lamivudine are rare and reported to be
around 9%.
Case report
A 29 year old HIV positive female was initiated on ART
on 5/11/2012 with first line regimen, (TDF+3TC+NVP)
as patient was anaemic. Patient came back with Nevira-
pine rash and ART was stopped on 20/12/12. Nevira-
pine was substituted with Efavirenz after rashes healed
on 2/1/13. Patient developed severe itching with rashes
just after three doses and hence ART was stopped. After
one month, she was counseled, hospitalized and was
rechallenged with only TDF+3TC; patient again devel-
oped severe itching with only one dose. Hence, patient
was challenged with only lamivudine. With just one
dose of lamivudine, patient developed hypersensitivity
reaction within few hours with facial oedema, redness,
tightness of skin with maculopapular rash and general-
ized blanchable erythema, giddiness, and hypotension
and collapsed. She was resuscitated with dopamine, IV
fluids and antihistamines.
Conclusion
Nucleoside reverse transcriptase inhibitors (NRTIs) such
as lamivudine can cause skin rash in 1-10% of patients.
Lamivudine related cutaneous side effects are probably
under estimated. Lamivudine hitherto considered a safe
drug can cause serious side effects in some patients as
reported here. Hence, careful observation and timely
intervention is mandatory to avoid fatalities in those
patients receiving NRTI based antiretroviral therapy.
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